Recent Complete Response Letters (CRL) issued to Replimune and Capricor have made the FDA’s new and intensified scrutiny of clinical trial design clear. As the agency demands greater rigor and ...
Source: 21st Century Health (original reporting) The warmth spreading through China’s pharma space is now radiating downstream to the entire outsourcing chain. WuXi AppTec now expects 2025 top-line ...
After a multi-day winning streak, the CRO concept index hit a fresh high on 25 Jul. Porton (300363.SZ), Pharmaron (3759.HK) and Tigermed (300347.SZ) surged more than 5 %, with dozens of peers ...
